Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -5.33 is 143% below its 5-year average of -2.19, around the middle of its 5-year range (-19.72–23.54).
As of the fiscal period ended Tuesday, June 30, 2026. 15.25% above its 12-month average of -6.29.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): -5.33.
DEBT TO EQUITY RATIO
-5.33
DEBT TO EQUITY RATIO AVG TTM
-6.29
DEBT TO EQUITY RATIO AVG 3Y
-1.34
DEBT TO EQUITY RATIO AVG 5Y
-2.19
DEBT TO EQUITY RATIO AVG 10Y
-0.48
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+15.25%
CURRENT VS 3Y AVG
-298.03%
CURRENT VS 5Y AVG
-143.23%
CURRENT VS 10Y AVG
-1001.43%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 529 covered companies
CURRENT VS SECTOR MEDIAN
-4202.27%
vs the sector median at left
Evolus, Inc.
Market Cap
$474.81M
Debt to Equity Ratio
-5.33
TTM Avg
-6.29
3Y Avg
-1.34
5Y Avg
-2.19
Market Cap
$468.80M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$466.69M
Debt to Equity Ratio
0.03
TTM Avg
0.03
3Y Avg
0.07
5Y Avg
0.07
Market Cap
$463.91M
Debt to Equity Ratio
1.10
TTM Avg
1.63
3Y Avg
1.59
5Y Avg
1.34
Market Cap
$448.48M
Debt to Equity Ratio
0.57
TTM Avg
0.61
3Y Avg
0.62
5Y Avg
0.56
Market Cap
$498.75M
Debt to Equity Ratio
0.16
TTM Avg
0.24
3Y Avg
0.21
5Y Avg
0.16
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Evolus, Inc. (EOLS) | $474.81M | -5.33 | -6.29 | -1.34 | -2.19 |
| Bright Minds Biosciences Inc. (DRUG)vs › | $468.80M | 0.00 | 0.01 | 0.01 | 0.01 |
| Arvinas, Inc. (ARVN)vs › | $472.30M | 0.01 | 0.02 | 0.01 | 0.01 |
| Contineum Therapeutics, Inc. (CTNM)vs › | $466.69M | 0.03 | 0.03 | 0.07 | 0.07 |
| Cerus Corporation (CERS)vs › | $463.91M | 1.10 | 1.63 | 1.59 | 1.34 |
| NRC Health (NRC)vs › | $459.07M | 13.75 | 3.86 | 2.21 | 1.62 |
| Kamada Ltd. (KMDA)vs › | $456.36M | 0.04 | 0.04 | 0.06 | 0.07 |
| NeoGenomics, Inc. (NEO)vs › | $448.48M | 0.57 | 0.61 | 0.62 | 0.56 |
| Allogene Therapeutics, Inc. (ALLO)vs › | $498.75M | 0.16 | 0.24 | 0.21 | 0.16 |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $448.04M | 0.00 | 0.01 | 0.01 | 0.01 |
Debt/Equity
-5.33
Current Ratio
1.70
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -5.33 |
| 2026-03-31 | -5.73 |
| 2025-12-31 | -6.71 |
| 2025-09-30 | -5.39 |
| 2025-06-30 | -8.31 |
| 2025-03-31 | -19.72 |
| 2024-12-31 | 23.54 |
| 2024-09-30 | 22.05 |
| 2024-06-30 | 6.56 |
| 2024-03-31 | 6.87 |
| 2023-12-31 | -6.12 |
| 2023-09-30 | -5.24 |
| 2023-06-30 | -13.91 |
| 2023-03-31 | 10.70 |
| 2022-12-31 | 4.02 |
| 2022-09-30 | 2.55 |
| 2022-06-30 | 1.59 |
| 2022-03-31 | 1.11 |
| 2021-12-31 | 0.91 |
| 2021-09-30 | 0.24 |
| 2021-06-30 | 0.22 |
| 2021-03-31 | 1.01 |
| 2020-12-31 | -1.90 |
| 2020-09-30 | 3.92 |
| 2020-06-30 | 2.23 |
| 2020-03-31 | 1.55 |
| 2019-12-31 | 1.22 |
| 2019-09-30 | 5.64 |
| 2019-06-30 | 2.32 |
| 2019-03-31 | 1.20 |
| 2018-12-31 | -0.14 |
| 2018-09-30 | 0.18 |
| 2018-06-30 | 0.43 |
| 2018-03-31 | 0.31 |
| 2017-12-31 | -2.80 |
| 2017-09-30 | -2.61 |
| 2017-06-30 | -2.85 |
| 2017-03-31 | 0.00 |
| 2016-12-31 | -8.41 |
| 2016-09-30 | 0.00 |
| 2016-06-30 | 0.00 |
| 2016-03-31 | 0.00 |
